Third generation triplet cytotoxic chemotherapy in advanced non-small cell lung cancer: A systematic overview

Hatem A. Azim, Inas Elattar, Fausto R. Loberiza, Hamdy Azim, Tony Mok, Apar Kishor P Ganti

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Background: Previous meta-analysis on three drugs combination for treatment of advanced non-small cell lung cancer (NSCLC) did not demonstrate an improvement in survival, however many of the trials included in this meta-analysis used older and less effective cytotoxic drugs. We conducted this analysis to compare the relative efficacy of third generation triplet therapy with that of standard double therapy in the treatment of advanced NSCLC. Methods: A MEDLINE search was performed using the search terms "lung cancer" and "randomized trials". Trials not utilizing a third generation cytotoxic chemotherapeutic agent (paclitaxel, docetaxel, vinorelbine, gemcitabine) were excluded. Pooled odds ratios (OR) for the objective response and toxicity rates were calculated using the Mantel-Haenszel estimate. Pooled median ratios for median survival were calculated using the weighted sum of the log-ratio of median ratios of individual study. Results: We analyzed six randomized comparative trials involving 1932 patients. Patients receiving triplet therapy had a significantly higher response rate (OR: 1.33; 95% CI, 1.50-2.23; P < 0.001). Incidence of grade III/IV hematological toxicity was higher with triplet therapy. Non-hematological toxicities, with the exception of neuropathy, were similar. Median survival of triplet therapy was not significantly different from doublet (MR: 1.10; 95% CI: 0.91-1.35; P = 0.059). Conclusions: Triplet therapy with third generation cytotoxic drugs is associated with higher tumor response rate at the expense of increased toxicity. Although triplet therapy had a better overall survival compared to doublet therapy, this did not reach statistical significance.

Original languageEnglish (US)
Pages (from-to)194-198
Number of pages5
JournalLung Cancer
Volume64
Issue number2
DOIs
StatePublished - May 1 2009

Fingerprint

Non-Small Cell Lung Carcinoma
Drug Therapy
Therapeutics
Survival
docetaxel
gemcitabine
Meta-Analysis
Odds Ratio
Cytotoxins
Drug Combinations
Paclitaxel
MEDLINE
Pharmaceutical Preparations
Lung Neoplasms
Incidence

Keywords

  • Advanced non-small cell lung cancer
  • Cytotoxic chemotherapy
  • Doublet therapy
  • Outcomes
  • Overall survival
  • Response rates
  • Triplet therapy

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Third generation triplet cytotoxic chemotherapy in advanced non-small cell lung cancer : A systematic overview. / Azim, Hatem A.; Elattar, Inas; Loberiza, Fausto R.; Azim, Hamdy; Mok, Tony; Ganti, Apar Kishor P.

In: Lung Cancer, Vol. 64, No. 2, 01.05.2009, p. 194-198.

Research output: Contribution to journalArticle

Azim, Hatem A. ; Elattar, Inas ; Loberiza, Fausto R. ; Azim, Hamdy ; Mok, Tony ; Ganti, Apar Kishor P. / Third generation triplet cytotoxic chemotherapy in advanced non-small cell lung cancer : A systematic overview. In: Lung Cancer. 2009 ; Vol. 64, No. 2. pp. 194-198.
@article{074c04abc3394d72a86eb3ef92ecb7ce,
title = "Third generation triplet cytotoxic chemotherapy in advanced non-small cell lung cancer: A systematic overview",
abstract = "Background: Previous meta-analysis on three drugs combination for treatment of advanced non-small cell lung cancer (NSCLC) did not demonstrate an improvement in survival, however many of the trials included in this meta-analysis used older and less effective cytotoxic drugs. We conducted this analysis to compare the relative efficacy of third generation triplet therapy with that of standard double therapy in the treatment of advanced NSCLC. Methods: A MEDLINE search was performed using the search terms {"}lung cancer{"} and {"}randomized trials{"}. Trials not utilizing a third generation cytotoxic chemotherapeutic agent (paclitaxel, docetaxel, vinorelbine, gemcitabine) were excluded. Pooled odds ratios (OR) for the objective response and toxicity rates were calculated using the Mantel-Haenszel estimate. Pooled median ratios for median survival were calculated using the weighted sum of the log-ratio of median ratios of individual study. Results: We analyzed six randomized comparative trials involving 1932 patients. Patients receiving triplet therapy had a significantly higher response rate (OR: 1.33; 95{\%} CI, 1.50-2.23; P < 0.001). Incidence of grade III/IV hematological toxicity was higher with triplet therapy. Non-hematological toxicities, with the exception of neuropathy, were similar. Median survival of triplet therapy was not significantly different from doublet (MR: 1.10; 95{\%} CI: 0.91-1.35; P = 0.059). Conclusions: Triplet therapy with third generation cytotoxic drugs is associated with higher tumor response rate at the expense of increased toxicity. Although triplet therapy had a better overall survival compared to doublet therapy, this did not reach statistical significance.",
keywords = "Advanced non-small cell lung cancer, Cytotoxic chemotherapy, Doublet therapy, Outcomes, Overall survival, Response rates, Triplet therapy",
author = "Azim, {Hatem A.} and Inas Elattar and Loberiza, {Fausto R.} and Hamdy Azim and Tony Mok and Ganti, {Apar Kishor P}",
year = "2009",
month = "5",
day = "1",
doi = "10.1016/j.lungcan.2008.08.011",
language = "English (US)",
volume = "64",
pages = "194--198",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Third generation triplet cytotoxic chemotherapy in advanced non-small cell lung cancer

T2 - A systematic overview

AU - Azim, Hatem A.

AU - Elattar, Inas

AU - Loberiza, Fausto R.

AU - Azim, Hamdy

AU - Mok, Tony

AU - Ganti, Apar Kishor P

PY - 2009/5/1

Y1 - 2009/5/1

N2 - Background: Previous meta-analysis on three drugs combination for treatment of advanced non-small cell lung cancer (NSCLC) did not demonstrate an improvement in survival, however many of the trials included in this meta-analysis used older and less effective cytotoxic drugs. We conducted this analysis to compare the relative efficacy of third generation triplet therapy with that of standard double therapy in the treatment of advanced NSCLC. Methods: A MEDLINE search was performed using the search terms "lung cancer" and "randomized trials". Trials not utilizing a third generation cytotoxic chemotherapeutic agent (paclitaxel, docetaxel, vinorelbine, gemcitabine) were excluded. Pooled odds ratios (OR) for the objective response and toxicity rates were calculated using the Mantel-Haenszel estimate. Pooled median ratios for median survival were calculated using the weighted sum of the log-ratio of median ratios of individual study. Results: We analyzed six randomized comparative trials involving 1932 patients. Patients receiving triplet therapy had a significantly higher response rate (OR: 1.33; 95% CI, 1.50-2.23; P < 0.001). Incidence of grade III/IV hematological toxicity was higher with triplet therapy. Non-hematological toxicities, with the exception of neuropathy, were similar. Median survival of triplet therapy was not significantly different from doublet (MR: 1.10; 95% CI: 0.91-1.35; P = 0.059). Conclusions: Triplet therapy with third generation cytotoxic drugs is associated with higher tumor response rate at the expense of increased toxicity. Although triplet therapy had a better overall survival compared to doublet therapy, this did not reach statistical significance.

AB - Background: Previous meta-analysis on three drugs combination for treatment of advanced non-small cell lung cancer (NSCLC) did not demonstrate an improvement in survival, however many of the trials included in this meta-analysis used older and less effective cytotoxic drugs. We conducted this analysis to compare the relative efficacy of third generation triplet therapy with that of standard double therapy in the treatment of advanced NSCLC. Methods: A MEDLINE search was performed using the search terms "lung cancer" and "randomized trials". Trials not utilizing a third generation cytotoxic chemotherapeutic agent (paclitaxel, docetaxel, vinorelbine, gemcitabine) were excluded. Pooled odds ratios (OR) for the objective response and toxicity rates were calculated using the Mantel-Haenszel estimate. Pooled median ratios for median survival were calculated using the weighted sum of the log-ratio of median ratios of individual study. Results: We analyzed six randomized comparative trials involving 1932 patients. Patients receiving triplet therapy had a significantly higher response rate (OR: 1.33; 95% CI, 1.50-2.23; P < 0.001). Incidence of grade III/IV hematological toxicity was higher with triplet therapy. Non-hematological toxicities, with the exception of neuropathy, were similar. Median survival of triplet therapy was not significantly different from doublet (MR: 1.10; 95% CI: 0.91-1.35; P = 0.059). Conclusions: Triplet therapy with third generation cytotoxic drugs is associated with higher tumor response rate at the expense of increased toxicity. Although triplet therapy had a better overall survival compared to doublet therapy, this did not reach statistical significance.

KW - Advanced non-small cell lung cancer

KW - Cytotoxic chemotherapy

KW - Doublet therapy

KW - Outcomes

KW - Overall survival

KW - Response rates

KW - Triplet therapy

UR - http://www.scopus.com/inward/record.url?scp=63049099070&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63049099070&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2008.08.011

DO - 10.1016/j.lungcan.2008.08.011

M3 - Article

C2 - 18809226

AN - SCOPUS:63049099070

VL - 64

SP - 194

EP - 198

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 2

ER -